• Explore /
  • Poster
  • / Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study.

Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study.

Abstract Poster

Authors

null

Meinolf Karthaus

Department of Hematology and Oncology, Munich Hospital Neuperlach, Munich, Germany

Meinolf Karthaus , Lena Weiss , Jorge Riera-Knorrenschild , Albrecht Kretzschmar , Manfred Welslau , Ursula Vehling-Kaiser , Henning Pelz , Thomas Jens Ettrich , Swantje Held , Linde Kehrmann , Juergen Hess , Timo Reislaender , Volker Heinemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

EudraCT No 2017-000292-83

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3556)

DOI

10.1200/JCO.2023.41.16_suppl.3556

Abstract #

3556

Poster Bd #

256

Abstract Disclosures

Similar Posters

First Author: Kangho Suh

First Author: Timothy Jay Price

First Author: Kangho Suh

First Author: Meinolf Karthaus